---
type Props = {};

const {} = Astro.props;
---

<div class="references">
  <div class="wrapper">
    <div class="references__content">
      <slot>
        <p>
          <strong>References: 1.</strong> STRENSIQ. Package insert. Alexion Pharmaceuticals, Inc. <strong>2.</strong> NIH MedlinePlus. ALPL gene. 2023. Accessed April 3, 2023. Updated Feb 16, 2021. https://medlineplus.gov/genetics/gene/alpl/#conditions <strong>3.</strong> Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(suppl 2):380-388. <strong>4.</strong> Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65(10):1522-1530. <strong>5.</strong> Hӧgler W, Langman C, Gomes da Silva H, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20(1):80. <strong>6.</strong> Bianchi ML, Bishop NJ, Guañabens N, et al. Rare Bone Disease Action Group of the European Calcified Tissue Society Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. Osteoporos Int. 2020;31(8):1445–1460.
          <strong>7.</strong> McKiernan FE, Berg RL, Fuehrer J. Clinical and radiographic findings in adults with persistent hypophosphatasemia. J Bone Miner Res. 2014;29(7):1651–1660.
          <strong>8.</strong> Rush ET, Moseley S, Petryk A. Burden of disease in pediatric patients with hypophosphatasia: results from the HPP Impact Patient Survey and the HPP Outcomes Study Telephone interview. Orphanet J Rare Dis. 2019;16;14(1):201.
        </p>
      </slot>
    </div>
  </div>
</div>
